紫杉醇联合顺铂化疗方案在晚期食道癌治疗中的临床应用价值分析  

THE CLINICAL EFFECT OF ANALYSIS OF TAXOL COMBINED WITH CISPLATIN CHEMOTHERAPY IN THE TREATMENT OF ADVANCED ESOPHAGEAL CANCER

作　　者：王佩[1] 

机构地区：[1]河南省新乡市中心医院肿瘤科,新乡453000

出　　处：《现代预防医学》2011年第24期5139-5140,共2页Modern Preventive Medicine

摘　　要：[目的]探讨紫杉醇与顺铂联合化疗方案治疗晚期食道癌（Advanced esophageal cancer）的临床疗效、不良反应及对生活质量的改善程度。[方法]2007年9月~2010年12月间新乡市中心医院收治并诊断为晚期食道癌患者150例,随机分为观察组和对照组,其中观察组75例,采用紫杉醇与顺铂联合化疗方案;对照组采用顺铂联合氟尿嘧啶方案,评定治疗效果。[结果]按Kamofsky分级标准,观察组评分增高比例为34.7%（26/75）,平均生存时间为（9.8±4.3）个月,均明显优于对照组（P﹤0.05）。两组反应差异无统计学意义（P﹥0.05）。[结论]紫杉醇与顺铂联合化疗治疗晚期食道癌疗效显著,可明显改善患者的生活质量。[Objective]To explore the clinical effect of analysis of taxol combined with cisplatin chemotherapy in the treatment of advanced esophageal cancer.[Methods]From September 2007 to December 2010,150 cases of patients with esophageal cancer were were randomly divided into trial group and control group,including observation group 75 cases,using paclitaxel and cisplatin combination chemotherapy regimens;Control group was used by cisplatin plus 5-fluorouracil scheme,and then we evaluated the treatment effect.[Results]According to the Kamofsky standard,the observation group score with higher proportion was 34.7%（26/75）,and the mean survival time was 9.8± 4.3,which was much better than control group（P﹤0.05）. Two groups of reaction difference was statistically significant（P﹥0.05）.[Conclusion]Effect of paclitaxel and cisplatin chemotherapy in treatment of advanced esophageal cancer curative is distinct,and it can greatly improve the quality of life of the patients.

关 键 词：紫杉醇 顺铂 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]